NCLT Mumbai Bench orders approval of Arch Pharmalabs' resolution plan despite objections, directing monetary compensation for disputed goods.
The plan approval is not stalled as goods can be quantified monetarily, with one expired drum to be removed by the applicant.
Arch Pharmalabs is operating three of its six plants, with a pending US FDA inspection for further licensing requirements.
Objecting party granted ten days to file objections against the report, with next hearing scheduled for 04 June 2026.